Knight Therapeutics to Announce Q3 2024 Financial Results Soon
Upcoming Fourth Quarter 2024 Results Conference Call
Knight Therapeutics Inc. (TSX: GUD), a prominent pan-American specialty pharmaceutical company, is preparing to announce its financial results for the third quarter of 2024. The announcement will take place on a Thursday in November, prior to the market opening. Following the release of the results, a conference call and audio webcast will be held, inviting all stakeholders to join the discussion.
Conference Call Details
On the day of the results announcement, the conference call is scheduled for 8:30 a.m. ET. Participants can join through a toll-free number or an international dial-in option. Attendees will also have the ability to access a webcast, intended for listening only. This webcast will require a media player for the broadcast.
Replay Information
For those unable to attend the live call, Knight Therapeutics will offer an archived replay of the conference call. This replay will be accessible for 30 days after the initial event, providing flexibility for interested parties to catch up on the discussion.
About Knight Therapeutics Inc.
Headquartered in Montreal, Canada, Knight Therapeutics Inc. is dedicated to acquiring, in-licensing, and commercializing pharmaceutical products specifically for Canada and Latin America. The company operates various subsidiaries in Latin America, including United Medical, Biotoscana Farma, and Laboratorio LKM. Knight Therapeutics trades on the TSX under the symbol GUD.
Company Leadership
The leadership team at Knight Therapeutics includes President & Chief Executive Officer, Samira Sakhia, and Chief Financial Officer, Arvind Utchanah. Both leaders are committed to steering the company towards new horizons in pharmaceuticals and ensuring the growth of its product pipeline across the Americas.
Investor Contacts
For further inquiries, the contact details for the company's investor relations team are as follows. Samira Sakhia can be reached at 514.484.4483, while Arvind Utchanah can be contacted at +598.2626.2344. General inquiries can also be forwarded to the company's email address, IR@knighttx.com.
Future Outlook
As Knight Therapeutics approaches its results announcement, stakeholders are eager to learn about the company’s performance and future strategies. The third quarter's results will provide insight into Knight’s ongoing commitment to growth in the pharmaceutical sector.
Frequently Asked Questions
What is the date of the upcoming conference call?
The conference call will occur on a Thursday in November 2024, shortly after the financial results release.
How can I join the Knight Therapeutics conference call?
Participants can join the call via a toll-free telephone number or international lines, details of which will be provided prior to the event.
Where can I find the archived replay of the conference call?
The archived replay will be accessible on Knight Therapeutics' website for 30 days after the call.
Who are the key leaders of Knight Therapeutics?
The key leaders include Samira Sakhia, President & Chief Executive Officer, and Arvind Utchanah, Chief Financial Officer.
What is the main focus of Knight Therapeutics as a company?
Knight Therapeutics focuses on acquiring, in-licensing, and commercializing pharmaceutical products targeting Canada and Latin America.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
